Molecular investigation of exoU and exoY virulence genes in Pseudomonas aeruginosa collected from hospitalized patients in North of Iran: A descriptive-analytical study

Abstract

Objective: To investigate the frequency of exoU and exoY genes in patients with Pseudomonas aeruginosa infection. Methods: In this study, 100 clinical isolates of Pseudomonas aeruginosa were collected from patients hospitalized in educational-therapeutic hospitals and were identified using standard microbiological tests. Then, the antibiotic resistance pattern of the isolates was determined by the disk agar diffusion method. The bacterial DNAs were extracted by the alkaline lysis method. Finally, the presence of exoU and exoY genes was evaluated by the PCR test. Results: In this study, 47%, 72%, 29%, 39%, 40%, and 44% of the isolates were non-susceptible to piperacillin, aztreonam, ceftazidime, imipenem, tobramycin, and ciprofloxacin, respectively. In addition, 95% and 93% of the clinical isolates carried the exoU and exoY genes. Blood and fecal isolates had both virulence genes, while only one wound isolate had neither genes. Meanwhile, all urinary isolates contained the exoY gene and only one isolate lacked the exoU gene. Also, 88 isolates simultaneously had both exoU and exoY genes. Conclusions: High prevalence of exoU and exoY genes in this region indicates a significant role of type III secretion system in pathogenesis of Pseudomonas aeruginosa. The type III secretion system may be a suitable target to reduce the pathogenicity of this bacterium.

Keywords

Pseudomonas aeruginosa / exoU / exoY / Virulence gene / Type III secretion system / PCR

References

[1] del Mar Cendra M, Torrents E. Pseudomonas aeruginosa biofilms and their partners in crime. Biotechnol Ad 2021; 49: 107734.

[2] Wood SJ, Kuzel TM, Shafikhani SH. Pseudomonas aeruginosa: Infections, animal modeling, and therapeutics. Cells 2023; 12(1): 199.

[3] Shrivastava SR, Shrivastava PS, Ramasamy J. World health organization releases global priority list of antibiotic—resistant bacteria to guide research, discovery, and development of new antibiotics. J Med Soc 2018; 32(1): 76-77.

[4] Mohamed MF, Gupta K, Goldufsky JW, Roy R, Callaghan LT. CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoT. Nat Comm 2022; 13(1): 1295.

[5] Wood SJ, Goldufsky JW, Seu MY, Dorafshar AH, Shafikhani SH. Pseudomonas aeruginosa cytotoxins: Mechanisms of cytotoxicity and impact on inflammatory responses. Cells 2023; 12(1): 195.

[6] Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: The balancing act of BCL—2 family proteins. Nat Rev Mol Cell Biol 2019; 20(3): 175-193.

[7] Jørgensen R, Wang Y, Visschedyk D, Merrill AR. The nature and character of the transition state for the ADP—ribosyltransferase reaction. EMBO Rep 2008; 9(8): 802-809.

[8] Hogardt M, Heesemann J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int J Med Microbiol 2010; 300(8): 557-562.

[9] Burstein D, Satanower S, Simovitch M, Belnik Y, Zehavi M, Yerushalmi G, et al. Novel type III effectors in Pseudomonas aeruginosa. MBio 2015; 6(2): 10.1128/mbio.00161-00115.

[10] Finck—Barbançon V, Goranson J, Zhu L, Sawa T, Wiener—Kronish J, Fleiszig SM, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997; 25: 547-557.

[11] Foulkes DM, McLean K, Haneef AS, Fernig DG, Winstanley C, Berry N, et al. Pseudomonas aeruginosa toxin ExoU as a therapeutic target in the treatment of bacterial infections. Microorganisms 2019; 7(12): 707.

[12] Lindsey AS, Sullivan LM, Housley NA, Koloteva A, King JA, Audia JP, et al. Analysis of pulmonary vascular injury and repair during Pseudomonas aeruginosa infection—induced pneumonia and acute respiratory distress syndrome. Pulm Circ 2019; 9(1): 2045894019826941.

[13] Diaz MH, Hauser AR. Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. Infect Immun 2010; 78(4): 1447-1456.

[14] Sutterwala FS, Mijares LA, Li L, Ogura Y, Kazmierczak BI, Flavell RA. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. Exp Med 2007; 204(13): 3235-3245.

[15] Beckert U, Wolter S, Hartwig C, Bähre H, Kaever V, Ladant D, et al. ExoY from Pseudomonas aeruginosa is a nucleotidyl cyclase with preference for cGMP and cUMP formation. Biochem Biophys Res Commun 2014; 450(1): 870-874.

[16] Jeon J, Kim YJ, Shin H, Ha UH. T3SS effector ExoY reduces inflammasome—related responses by suppressing bacterial motility and delaying activation of NF—κB and caspase—1. FEBS J 2017; 284(20): 3392-3403.

[17] Wagener BM, Anjum N, Christiaans SC, Banks ME, Parker JC, Threet AT, et al. Exoenzyme Y contributes to end—organ dysfunction caused by Pseudomonas aeruginosa pneumonia in critically ill patients: An exploratory study. Toxins 2020; 12(6): 369.

[18] Kloth C, Schirmer B, Munder A, Stelzer T, Rothschuh J, Seifert R. The role of Pseudomonas aeruginosa ExoY in an acute mouse lung infection model. Toxins 2018; 10(5): 185.

[19] Tille P. Bailey & Scott’s diagnostic microbiology—E—Book. Elsevier Health Sciences; 2015.

[20] Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. 33rd ed. CLSI supplement M100—S33; 2023, 43.

[21] Ahmadian L, Haghshenas MR, Mirzaei B, Norouzi Bazgir Z, Goli HR. Distribution and molecular characterization of resistance gene cassettes containing class 1 integrons in multi—drug resistant (MDR) clinical isolates of Pseudomonas aeruginosa. Infect Drug Resist 2020; 2773-2781.

[22] Kaszab E, Szoboszlay S, Dobolyi C, Háhn J, Pék N, Kriszt B. Antibiotic resistance profiles and virulence markers of Pseudomonas aeruginosa strains isolated from composts. Bioresour Technol 2011; 102(2): 1543-1548.

[23] Zeng B, Wang C, Zhang P, Guo Z, Chen L, Duan K. Heat shock protein DnaJ in Pseudomonas aeruginosa affects biofilm formation via pyocyanin production. Microorganisms 2020; 8(3): 395.

[24] Hauser AR, Cobb E, Bodí M, Mariscal D, Vallés J, Engel JN, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator—associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30(3): 521-528.

[25] Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004; 42(11): 5229-5237.

[26] Jain M, Bar—Meir M, McColley S, Cullina J, Potter E, Powers C, et al. Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: A paradigm of chronic infection. Trans Res 2008; 152(6): 257-264.

[27] Bahador N, Shoja S, Faridi F, Dozandeh—Mobarrez B, Qeshmi FI, Javadpour S, et al. Molecular detection of virulence factors and biofilm formation in Pseudomonas aeruginosa obtained from different clinical specimens in Bandar Abbas. Iran J Microbiol 2019; 11(1): 25.

[28] Firouzi DL, Pooladi M, Nowroozi J, Akhavan SA, Hooshiyar M. Presence of exoU and exoS genes in Pseudomonas aeruginosa isolated from urinary tract infections. Infect Epidemiol Med 2016; 2(2): 8-11.

[29] Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 2000; 68(7): 3998-4004.

[30] Silistre H, Raoux—Barbot D, Mancinelli F, Sangouard F, Dupin A, Belyy A, et al. Prevalence of ExoY activity in Pseudomonas aeruginosa reference panel strains and impact on cytotoxicity in epithelial cells. Front Microbio 2021; 12: 666097.

[31] Yousefi—Avarvand A, Khashei R, Ebrahim—Saraie HS, Emami A, Zomorodian K, Motamedifar M. The frequency of exotoxin A and exoenzymes S and U genes among clinical isolates of Pseudomonas aeruginosa in Shiraz, Iran. Int J Mol Cell Med 2015; 4(3): 167.

[32] Azimi S, Kafil HS, Baghi HB, Shokrian S, Najaf K, Asgharzadeh M, et al. Presence of exoY, exoS, exoU and exoT genes, antibiotic resistance and biofilm production among Pseudomonas aeruginosa isolates in Northwest Iran. GMS Hyg Infect Control 2016; 11. doi: 10.3205/dgkh000264. eCollection 2016.

[33] Finck—Barbançon V, Frank DW. Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU. J Bacteriol 2001; 183(14): 4330-4344.

[34] Haghi F, Zeighami H, Monazami A, Toutouchi F, Nazaralian S, Naderi G. Diversity of virulence genes in multidrug resistant Pseudomonas aeruginosa isolated from burn wound infections. Microb Pathog 2018; 115: 251-256.

[35] Horna G, Amaro C, Palacios A, Guerra H, Ruiz J. High frequency of the exoU+/exoS+ genotype associated with multidrug—resistant “high—risk clones” of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals. Sci Rep 2019; 9(1): 10874.

[36] Subedi D, Vijay AK, Kohli GS, Rice SA, Willcox M. Association between possession of ExoU and antibiotic resistance in Pseudomonas aeruginosa. PLoS One 2018; 13(9): e0204936.

[37] Song Y, Mu Y, Wong NK, Yue Z, Li J, Yuan M, et al. Emergence of hypervirulent Pseudomonas aeruginosa pathotypically armed with co—expressed T3SS effectors ExoS and ExoU. hLife 2023. DOI: 10.1016/j.hlife.2023.02.001.

[38] Ullah R, Amir M, Anjum S, Rehman MU, Hasan TN, Naqvi SS, et al. Presence of T3SS (exoS, exoT, exoU and exoY), susceptibility pattern and MIC of MDR—Pseudomonas aeruginosa from burn wounds. J Infect Dev Ctries 2023; 17(8): 1130-1137.

[39] Zarei O, Shokoohizadeh L, Hossainpour H, Alikhani MY. Molecular analysis of Pseudomonas aeruginosa isolated from clinical, environmental and cockroach sources by ERIC—PCR. BMC Res Notes 2018; 11(1): 1-7.

[40] Goldufsky J, Wood SJ, Jayaraman V, Majdobeh O, Chen L, Qin S, et al. Pseudomonas aeruginosa uses T3SS to inhibit diabetic wound healing. Wound Repair Regen 2015; 23(4): 557-564.